Lhila Sunil, Pande Arindam, Kumar Rohit, Bhureddy Swathi, Sanghavi Arti, Katare Sagar, Shah Jay, Shah Snehal, Verma Garima
Cardiology, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, IND.
Cardiology, Medica Superspecialty Hospital, Kolkata, IND.
Cureus. 2025 Jul 29;17(7):e88954. doi: 10.7759/cureus.88954. eCollection 2025 Jul.
Hypertension is a lifestyle disorder with a target blood pressure (BP) <140/90 mmHg. Amlodipine, a calcium channel blocker (CCB), is the first-line choice of treatment. This study aims to assess the effectiveness, tolerability, and treatment pattern of amlodipine or its combinations in patients with hypertension.
This retrospective, electronic medical records (EMR)-based longitudinal study analyzed anonymized data of hypertensive patients with prescriptions for amlodipine or its combinations. The primary aim was to understand the usage patterns, while the secondary goals were to assess effectiveness and tolerability. Outcome measures included changes in mean systolic BP (SBP) and diastolic BP (DBP), and the incidence of pedal edema.
Most of the participants were aged 40 to 64 years (65.47%) and were predominantly male (52.85%). Dyslipidemia and diabetes mellitus (DM) were the most common comorbidities. There was a statistically significant reduction in SBP and DBP from visit 1 to visit 2 with amlodipine or its combination therapies (p < 0.001), irrespective of any comorbid condition. Pedal edema occurred in 0.91% of patients, notably lower than the reported 1.7%-32%.
Amlodipine or its combinations demonstrated a significant reduction in BP with a very low incidence of pedal edema. Hence, amlodipine shows good tolerability and effectiveness in the Indian population.
高血压是一种生活方式紊乱疾病，目标血压（BP）<140/90 mmHg。氨氯地平，一种钙通道阻滞剂（CCB），是一线治疗选择。本研究旨在评估氨氯地平及其联合用药在高血压患者中的有效性、耐受性和治疗模式。
这项基于电子病历（EMR）的回顾性纵向研究分析了有氨氯地平或其联合用药处方的高血压患者的匿名数据。主要目的是了解使用模式，次要目标是评估有效性和耐受性。结局指标包括平均收缩压（SBP）和舒张压（DBP）的变化以及足踝水肿的发生率。
大多数参与者年龄在40至64岁之间（65.47%），且男性居多（52.85%）。血脂异常和糖尿病（DM）是最常见的合并症。无论有无合并症，使用氨氯地平或其联合治疗方案后，从第1次就诊到第2次就诊时SBP和DBP均有统计学显著降低（p < 0.001）。0.91%的患者出现足踝水肿，明显低于报道的1.7%-32%。
氨氯地平及其联合用药显示出血压显著降低，足踝水肿发生率极低。因此，氨氯地平在印度人群中显示出良好的耐受性和有效性。
